|D012120||Respiration Disorders NIH||0.22|
|D012140||Respiratory Tract Diseases NIH||0.20|
There is one clinical trial.
This study is a randomized, double-blind, parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory complications
Description: The 6MWT is a validated endpoint commonly used in clinical trial researchMeasure: Change in distance walked on the six-minute walk test (6MWT) Time: Baseline to Day 91
Description: The mBDS is an assessment tool that analyzes breathlessness under exertionMeasure: Change in Modified Borg Dyspnoea Scale (mBDS) score Time: Baseline to Day 91
Description: The SF-36 (v2) is a self-administered questionnaire containing 36 items that measures functional status, well-being and overall evaluation of health in 8 domainsMeasure: Quality of Life assessment as collected using the SF-36 Time: Baseline to Day 91
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports